The Brussels International Declaration on Lipoprotein(a) Testing and Management
Innsbruck Medical University · Health Action International · +33 more institutions
Abstract
There is striking evidence that a high lipoprotein(a) [Lp(a)] concentration is a strong, independent, and causal cardiovascular risk factor. However, Lp(a) testing rates are very low (1 %-2 %) despite the fact that 1 in 5 individuals have elevated Lp(a) concentrations. The Brussels International Declaration on Lp(a) Testing and Management was co-created by the Lp(a) International Task Force and global leaders at the Lp(a) Global Summit, held in Brussels, Belgium, on March 24-25, 2025. The event, organized by FH Europe Foundation, brought together scientific experts, people with the lived experience of elevated Lp(a) and policy makers from the European Institutions and World Health Organization. The World Heart…
Citation impact
- FWCI
- 84.43
- Percentile
- 100%
- References
- 57
Authors
40Topics & keywords
- Declaration
- Business
- Political science
- Law
- Partnerships for the goals
Funding
- AAmgen
- ELEli Lilly and Company
- AAstraZeneca
- SSanofi
- CBCSL Behring
- RPRegeneron Pharmaceuticals
- UPUltragenyx Pharmaceutical
- PTPTC Therapeutics
- EFEuropean Federation of Pharmaceutical Industries and Associations
- ACAmarin Corporation
- AAnthera
- MCMedicines Company
- KCKowa Company
- APAmryt Pharma
- IInfraRedx
- ICImperial College London
- DDaiichi-Sankyo
- NNNovo Nordisk
- SHSiemens Healthineers
- SOSwedish Orphan Biovitrum
- HTHLS Therapeutics
- STSilence Therapeutics
- ETEsperion Therapeutics
- SSeqirus
- GGenentech
- ADAbbott Diagnostics
- DSDaiichi Sankyo Europe